Prevalence of metabolic syndrome in behçet disease: A case-control study in Turkey

American Journal of Clinical Dermatology

Volumn 14, Issue 5, 2013, Pages 421-425

  Yalçın, Başak ^a,c   Gür, Güneş ^b   Artüz, Ferda ^b   Allı, Nuran ^b  

^a YILDIRIM BEYAZIT UNIVERSITY   (Turkey)

^b ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^c NONE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; BEHCET DISEASE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; ONSET AGE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; TURKEY (REPUBLIC); WAIST CIRCUMFERENCE;

ADULT; AGE FACTORS; BEHCET SYNDROME; BODY MASS INDEX; CASE-CONTROL STUDIES; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NERVOUS SYSTEM DISEASES; PREVALENCE; RISK FACTORS; SEX FACTORS; TURKEY;

EID: 84884957366     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.1007/s40257-013-0034-8     Document Type: Article

References (20)

1. Alli N, Gur G, Yalcin B, Hayran M. Patient characteristics in Behçet disease: a retrospective analysis of 213 Turkish patients during 2001-4. Am J Clin Dermatol. 2009;10(6):411-8.
2. Pineton de Chambrun M, Wechsler B, Geri G, Cacoub P, Saadoun D. New insights into the pathogenesis of Behçet's disease. Autoimmun Rev. 2012;10:687-98.
3. Yalcin B, Atakan N, Alli N. The functional role of nuclear factor kappa-kappaB1-94 ins/del ATTG promotor gene polymorphism in Behçet's disease: an exploratory study. Clin Exp Dermatol. 2008;33(5):629-33.
4. Akman A, Sallaci N, Coskun M, Bacanli A, Yavuzer U, Alpsoy E, Yegin O. TNF-alpha gene 1031 T/C polymorphism in Turkish paients with Behcet's disease. Br J Dermatol. 2006;155:350-6.
5. Prasad H, Ryan DA, Celzo MF, Stapleton D. Metabolic syndrome: definition and therapeutic implications. Postgrad Med. 2012;124:21-30.
6. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung and Blood Institute Scientific Statement. Circulation. 2005;112:2735-52.
7. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol. doi: 10.1016/j.jaad.2012.08.015.
8. Cunha VR, Brenol CV, Brenol JCT, Fuchs SC, Arlindo EM, Melo IMF, Machado CA, Chaves H, Xavier RM. Metabolic syndrome prevalence is increased in rheumatoid arthritis patients and is associated with disease activity. Scan J Rheumatol. 2012;41:186-91.
9. Nagahori M, Hyun SB, Totsuka T, Ryuichi O, Kuwahar E, Takebayashi T, Naganuma M, Watanabe M. Prevalance of metabolic syndrome is comparable between inflammatory bowel disease patients and the general population. J Gastroenterol. 2010;45:1008-13.
10. Kim SK, Choe JY, Park SH, Lee SW, Lee GH, Chung WT. Increased insulin resistance and serum resistin in Korean patients with Behçet's disease. Arch Med Res. 2010;41:269-74.
11. International study group for Behcet's disease. Criteria for diagnosis of Behcet's disease. Lancet. 1999;335:1078-80.
12. Cho SB, Cho S, Bang D. New insights in the clinical understanding of Behçet's disease. Yonsei Med J. 2012;53:35-42.
13. Demiroǧlu H, Yalçin S, Büyükaşik Y, Ozcebe OI, Dündar S. Increased erythrocyte aggregation as an indicator for an aggressive clinical course in Behçet's disease: a prospective study. Ann Rheum Dis. 1998;57(11):694-6.
14. Saadoun D, Wechsler B, Desseaux K, Huong LT, Amoura Z, Rigon M, Cacoub P. Mortality in Behçet's disease. Arthritis Rheumat. 2010;62:2806-12.
15. Ekelund U, Anderssen S, Andersen LB, Riddoch CJ, Sardinha LB, Luan J. Prevalence and correlates of the metabolic syndrome in a population- based sample of European youth. Am J Clin Nutr. 2009;89:90-6.
16. Centis E, Marzocchi R, Suppini A, Grave RD, Villanova N, Hickman IJ, Marchesini G. The role of lifestyle change in the prevention and treatment of NAFLD. Curr Pharm Des. 2013 (Epub ahead of print).
17. Zhao YF, Feng DD, Chen C. Contribution of adipocyte- derived factors to beta-cell dysfunction in diabetes. Int J Biochem Cell Biol. 2006;38:804-19.
18. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest. 2005;115:1111-9.
19. Stagakis I, Bertsias G, Karvounaris S, Kavousanaki M, Virla D, Raptopoulou A, Kardassis D. Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance. Arthritis Res Ther. 2012;14:R141.
20. Carroll S, Dudfield M. What is the relationship between exercise and metabolic abnormalities? A review of the metabolic syndrome. Sport Med. 2004;34:371-418.